AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Niclosamide exerted inhibitory effect on transduction of BCR-ABL pathway as indicated by the reduced phospho-STAT5 and phospho-Akt in the niclosamide-treated CML cell regardless of BCR-ABL mutation status.